Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study

Cancer ◽  
1993 ◽  
Vol 72 (5) ◽  
pp. 1733-1742 ◽  
Author(s):  
Lothar Bergmann ◽  
Klaus Fenchel ◽  
Eckhart Weidmann ◽  
Hans-Martin Enzinger ◽  
Bernhard Jahn ◽  
...  
Keyword(s):  
Phase Ii ◽  
Renal Cell Cancer ◽  
Renal Cell ◽  
Phase Ii Study ◽  
Cell Cancer ◽  
Interleukin 2 ◽  
High Dose ◽  
Bolus Infusion ◽  
Metastatic Renal Cell Cancer

An Outpatient Phase II Study of Subcutaneous Interleukin-2 and Interferon-Alpha-2b in Combination with Intravenous Vinblastine in Metastatic Renal Cell Cancer

Oncology ◽  
1997 ◽  
Vol 55 (1) ◽  
pp. 10-15 ◽  
Author(s):  
D. Pectasides ◽  
J. Varthalitis ◽  
M. Kostopoulou ◽  
A. Mylonakis ◽  
D. Triantaphyllis ◽  
...  
Keyword(s):  
Interferon Alpha ◽  
Phase Ii ◽  
Renal Cell Cancer ◽  
Renal Cell ◽  
Phase Ii Study ◽  
Cell Cancer ◽  
Interleukin 2 ◽  
Metastatic Renal Cell Cancer ◽  
Interferon Alpha 2B

Continuous-infusion fluorodeoxyuridine with leucovorin and high-dose interferon: a phase II study in metastatic renal-cell cancer

1992 ◽  
Vol 31 (3) ◽  
pp. 213-216 ◽  
Author(s):  
Walter M. Stadler ◽  
Nicholas J. Vogelzang ◽  
Everett E. Vokes ◽  
Jane Charette ◽  
Greg Whitman
Keyword(s):  
Continuous Infusion ◽  
Phase Ii ◽  
Renal Cell Cancer ◽  
Renal Cell ◽  
Phase Ii Study ◽  
Cell Cancer ◽  
High Dose ◽  
Metastatic Renal Cell Cancer ◽  
High Dose Interferon

Should High-Dose Interleukin-2 Still be the Preferred Treatment for Patients with Metastatic Renal Cell Cancer?

2011 ◽  
Vol 26 (3) ◽  
pp. 273-277 ◽  
Author(s):  
Robert O. Dillman ◽  
Neil M. Barth ◽  
Louis A. VanderMolen ◽  
Warren H. Fong ◽  
Khosrow K. Mahdavi ◽  
...  
Keyword(s):  
Renal Cell Cancer ◽  
Renal Cell ◽  
Cell Cancer ◽  
Interleukin 2 ◽  
High Dose ◽  
Metastatic Renal Cell Cancer

Metastatic renal cell cancer treated with low-dose interleukin-2. A phase-II multicentre study

1989 ◽  
Vol 16 ◽  
pp. 111-113 ◽  
Author(s):  
G. Stoter ◽  
S.D. Fosså ◽  
C. Rugarli ◽  
M. Symann ◽  
C. Jasmin ◽  
...  
Keyword(s):  
Multicentre Study ◽  
Phase Ii ◽  
Renal Cell Cancer ◽  
Renal Cell ◽  
Low Dose ◽  
Cell Cancer ◽  
Interleukin 2 ◽  
Metastatic Renal Cell Cancer

scholarly journals Phase II study of individualized sunitinib (SUN) as first-line therapy for metastatic renal cell cancer: Pharmacokinetic data

2017 ◽  
Vol 28 ◽  
pp. v319
Author(s):  
G.A. Bjarnason ◽  
J. Knox ◽  
C.K. Kollmannsberger ◽  
D. Soulieres ◽  
D.S. Ernst ◽  
...  
Keyword(s):  
Phase Ii ◽  
Renal Cell Cancer ◽  
Renal Cell ◽  
Phase Ii Study ◽  
Cell Cancer ◽  
Pharmacokinetic Data ◽  
First Line ◽  
Metastatic Renal Cell Cancer ◽  
First Line Therapy ◽  
Line Therapy

A phase II study of dovitinib (TKI258), an FGFR- and VEGFR-inhibitor, in patients with advanced or metastatic renal cell cancer (mRCC).

2011 ◽  
Vol 29 (15_suppl) ◽  
pp. 4551-4551 ◽  
Author(s):  
E. Angevin ◽  
V. Grünwald ◽  
A. Ravaud ◽  
D. E. Castellano ◽  
C. C. Lin ◽  
...  
Keyword(s):  
Phase Ii ◽  
Renal Cell Cancer ◽  
Renal Cell ◽  
Phase Ii Study ◽  
Cell Cancer ◽  
Metastatic Renal Cell Cancer ◽  
Vegfr Inhibitor

Phase II study of individualized sunitinib as first-line therapy for metastatic renal cell cancer (mRCC).

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. 4555-4555 ◽  
Author(s):  
Georg A. Bjarnason ◽  
Jennifer J. Knox ◽  
Christian K. Kollmannsberger ◽  
Denis Soulieres ◽  
D. Scott Ernst ◽  
...  
Keyword(s):  
Phase Ii ◽  
Renal Cell Cancer ◽  
Renal Cell ◽  
Phase Ii Study ◽  
Cell Cancer ◽  
First Line ◽  
Metastatic Renal Cell Cancer ◽  
First Line Therapy ◽  
Line Therapy
Sign in / Sign up

Export Citation Format

Share Document